Anzeige
Mehr »
Donnerstag, 25.09.2025 - Börsentäglich über 12.000 News
Geheime Börsenchance: Ist das die bedeutendste Kupferentdeckung Kanadas?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PEFW | ISIN: KYG2588M1006 | Ticker-Symbol: PH4
Tradegate
25.09.25 | 08:15
0,890 Euro
+4,71 % +0,040
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
CSTONE PHARMACEUTICALS CO LTD Chart 1 Jahr
5-Tage-Chart
CSTONE PHARMACEUTICALS CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,8450,88021:30
0,8400,88021:30

Aktuelle News zur CSTONE PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CSTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln
DiCSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES FIRST PATIENT ENROLLMENT IN GLOBAL PHASE II TRIAL OF CS2009 (PD-1/VEGF/CTLA-4 TRISPECIFIC ...2
DiCSTONE PHARMA-B (02616): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION2
DiCSTONE PHARMA-B (02616): APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR3
15.09.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE TO SHOWCASE CS2015 (OX40L/TSLP BISPECIFIC ANTIBODY) AT ACAAI 202514
27.08.CSTONE PHARMA-B (02616): GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS21
14.08.CSTONE PHARMA-B (02616): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 202537
04.08.CSTONE PHARMA-B (02616): DATE OF BOARD MEETING10
28.07.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - ESMO 2025: CSTONE TO DEBUT CS2009 CLINICAL DATA AND CS5001 TRIAL DESIGN5
16.07.CSTONE PHARMA-B (02616): NEXT DAY DISCLOSURE RETURN13
16.07.CSTONE PHARMA-B (02616): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE11
10.07.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES NMPA APPROVAL FOR LOCALIZED MANUFACTURING OF GAVRETO (PRALSETINIB) IN CHINA5
09.07.CSTONE PHARMA-B (02616): PLACING OF NEW SHARES UNDER GENERAL MANDATE3
08.07.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE SIGNS EXCLUSIVE LICENSE AGREEMENT WITH ISTITUTO GENTILI FOR SUGEMALIMAB IN WESTERN EUROPE AND ...5
07.07.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CLINICAL PROGRESS UPDATE ON CS2009 (PD-1/VEGF/CTLA-4 TRISPECIFIC ANTIBODY)5
04.07.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - LATEST UPDATE ON GLOBAL MULTICENTER PHASE III STUDY OF NOFAZINLIMAB IN HEPATOCELLULAR CARCINOMA4
03.07.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE UNVEILS TWO BISPECIFIC ANTIBODY TARGETS FOR AUTOIMMUNE/INFLAMMATORY DISEASES5
25.06.CSTONE PHARMA-B (02616): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE10
25.06.CSTONE PHARMA-B (02616): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION4
25.06.CSTONE PHARMA-B (02616): (1) POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 25, 2025; (2) RETIREMENT AND RESIGNATION OF DIRECTORS; AND (3) CHANGE ...2
19.06.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - LONG-TERM SURVIVAL DATA OF GEMSTONE-302 TRIAL ON SUGEMALIMAB PUBLISHED IN THE LANCET ONCOLOGY9
Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1